153 related articles for article (PubMed ID: 38296623)
1. [Identification and Analysis of SND1 as an Oncogene and Prognostic Biomarker
for Lung Adenocarcinoma].
Zhang R; Huang H; Zhu G; Wu D; Chen C; Cao P; Ding C; Liu H; Chen J; Li Y
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):25-37. PubMed ID: 38296623
[TBL] [Abstract][Full Text] [Related]
2. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
3. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and immune infiltrative biomarkers of CENPO in pan-cancer and its relationship with lung adenocarcinoma cell proliferation and metastasis.
Wang Y; Ye D; Li Y; Lv F; Shen W; Li H; Tian L; Fan Z; Li Y; Wang Y; Li F; Chen Y
BMC Cancer; 2023 Aug; 23(1):735. PubMed ID: 37558987
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
6. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
7. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
8. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
[TBL] [Abstract][Full Text] [Related]
9. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with
Zhang YH; Liu XS; Gao Y; Yuan LL; Huang ZM; Zhang Y; Liu ZY; Yang Y; Liu XY; Ke CB; Pei ZJ
Lung Cancer; 2024 Feb; 188():107449. PubMed ID: 38184958
[TBL] [Abstract][Full Text] [Related]
10. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
11. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma.
Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S
Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773
[TBL] [Abstract][Full Text] [Related]
12. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
13. Identification of
Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
[TBL] [Abstract][Full Text] [Related]
14. G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension.
Ding R; Sang S; Yi J; Xie H; Wang F; Dai A
Aging (Albany NY); 2024 Jan; 16(1):466-492. PubMed ID: 38194707
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
16. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.
Li Y; Yang W; Liu C; Zhou S; Liu X; Zhang T; Wu L; Li X; Zhang J; Chang E
Int Immunopharmacol; 2024 May; 132():111918. PubMed ID: 38537539
[TBL] [Abstract][Full Text] [Related]
17. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
18. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation-associated LINC00987 downregulation induced lung adenocarcinoma progression by inhibiting the phosphorylation-mediated degradation of SND1.
Lai Q; Wan Y; Zhang Y; Huang Y; Tang Q; Chen M; Li Q; Ma K; Xiao P; Luo C; Zhuang X
Mol Carcinog; 2024 Apr; ():. PubMed ID: 38607240
[TBL] [Abstract][Full Text] [Related]
20. LINC01117 inhibits invasion and migration of lung adenocarcinoma through influencing EMT process.
Liu L; Ren W; Du L; Xu K; Zhou Y
PLoS One; 2023; 18(6):e0287926. PubMed ID: 37384755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
